The origin of proteinuria at high altitude

M.H. Winterborn, A.R. Bradwell, I.M. Chesner and G.T. Jones

Department of Paediatrics, East Birmingham Hospital, Bordesley Green East, Birmingham B9 5ST, UK.

Summary: Urinary protein excretion was measured before and after the intravenous infusion of lysine in 14 normal subjects after 4–6 days' acclimatization at 4846 m. Urinary albumin excretion before lysine was elevated in 11 subjects but alpha,-microglobulin was detected in only four. After lysine a large increase in albumin excretion occurred in all subjects. Together with the absence of alpha,-microglobulin before lysine this implies that increased glomerular capillary permeability is the major cause of proteinuria after acclimatization to high altitude. The estimated minimum glomerular fluid albumin concentration was increased two to three fold above the published values in normal controls.

Introduction

Increased albumin in the urine on ascent to high altitude has previously been demonstrated.1 We showed a significant correlation between the height attained and both the concentration and the excretion rate of urinary albumin in normal subjects after rapid ascent.2 The increase in albumin excretion rate was virtually abolished in subjects treated with acetazolamide. Variations in the albumin excretion rate were related closely to the degree of hypoxia. It is unknown whether this effect of hypoxia is mediated by increased glomerular capillary permeability or decreased tubular protein reabsorption.

It has been shown that intravenous lysine acts as a powerful but transient inhibitor of renal tubular protein reabsorption3 offering a means of distinguishing between tubular and glomerular proteinuria in normal man. The purpose of the present study was to determine the site of the renal protein leak and the effect of acetazolamide in normal subjects who had ascended recently to high altitude.

Methods

Fourteen men aged 23–45 years were studied after 4–6 days at 4846 m having walked to that altitude.4 Eight subjects were taking acetazolamide 500 mg once daily (Group A) and six a placebo (Group P) on a double blind basis. Following a fast of at least 4 hours subjects took 250 ml of clear fluid by mouth every 20 min during the test. After emptying the bladder a baseline 20-minute urine collection was made. L-lysine hydrochloride 30 g in 100 ml (chloride 180 mmol/l) was then infused over 10 min using 50 ml syringes and double 0.45 μm filters. A second timed urine collection was made during and for 20 minutes after the lysine infusion. A 21-gauge 'butterfly' needle in a forearm vein was used for the lysine infusion and for blood samples at the mid-points of the urine collection periods. Clotted blood was centrifuged and the serum separated. Urine volumes were measured and 3 ml aliquots taken. The serum and urine samples were preserved with sodium azide and transported back to Birmingham for analysis. Creatinine in blood and urine was determined by a centrifugal analyser. Albumin and alpha,-microglobulin were determined in urine by radial immunodiffusion. The increase in albumin excretion was expressed as a percentage of the rate after lysine (i.e. the rate approaching maximum filtration of albumin) rather than as a percentage of the baseline albumin rate. This allowed the protein subjected to tubular reabsorption to be expressed as a fraction of the total filtered. The statistical significance of differences between the groups was established by the Mann-Whitney rank-sum test. Results are expressed as mean ± standard deviation.

Results

Before lysine

Urine flow rate was 3.5 ± 3 ml/min in Group A and 0.52 ± 0.3 ml/min in Group P (P < 0.001). Creatinine clearance was 111.5 ± 64.3 ml/min in Group A and 49.5 ± 39.4 ml/min in Group P (P < 0.05). Albumin excretion rate was 59 ± 39 μg/min in Group A and 115 ± 198 μg/min in Group P (not significant). It exceeded the upper limit of normal (15 μg/min) in all of Group A but in only 3 of Group P (Figure 1).

Correspondence: M.H. Winterborn M.B., B.S., F.R.C.P.
microglobulin was detectable in the urine of only one subject in Group A and 3 in Group P.

The arterialized capillary \( P_{a, \text{O}_2} \), measured within 24 hours of the lysine study was 5.83 ± 0.35 kPa in Group A and 5.41 ± 0.35 kPa in Group P (\( P < 0.02 \)). There was no significant correlation between albumin excretion rate and \( P_{a, \text{O}_2} \) (\( r = 0.35 \)).

After lysine

Urine flow rate increased to 6.8 ± 4.2 ml/min in Group A and to 5.1 ± 5.9 ml/min in Group P but this was not accompanied by any significant change in creatinine clearance which was 111.8 ± 31.1 ml/min in Group A and 148.7 ± 171 ml/min in Group P. Albumin excretion rate increased (Figure 2) to 480 ± 250 \( \mu \)g/min in Group A and to 754 ± 954 \( \mu \)g/min in Group P with no significant difference between the groups. The amount by which albumin excretion increased, expressed as a fraction of the rate after lysine infusion, was 78 ± 19% in Group A and 74 ± 29% in Group P. The increase in albumin excretion was less than 60% in two members of each group. Only one had detectable alpha-1-microglobulin in his urine prior to lysine infusion. The increase in albumin excretion was accompanied by the appearance of alpha-1-microglobulin in the urine of every subject; in Group A the alpha-1-microglobulin excretion rate was 598 ± 325 \( \mu \)g/min and in Group P was 661 ± 571 \( \mu \)g/min.

An estimate of the minimum albumin concentration in glomerular fluid (GFA) was made in each subject using the measurements of creatinine clearance and albumin excretion in the urine after lysine infusion. In Group A the GFA was 5.0 ± 2.1 mg/l and in Group P it was 4.9 ± 1.8 mg/l (not significant) (Figure 3). In a repeat lysine infusion in one subject in UK the value was 3.4 mg/l.

Twenty-four hours after the study 12 of the 14 subjects noticed pain in the forearm vein which had been used for the infusion of lysine and the vein was found to be thrombosed, presumably due to local irritation by the hypertonic solution.

Discussion

Proteinuria is a constant finding in man after rapid ascent to altitudes in excess of 3,000 m. Previous
studies have shown a correlation between the quantity of proteinuria and both the degree of hypoxia and the height attained. Furthermore, it was shown that treatment with acetazolamide diminished high altitude proteinuria presumably by reducing hypoxia. However, the results of the present study, which was conducted after a slow ascent from 1500 m and acclimatization for four days at 4846 m showed no significant effect of acetazolamide on the proteinuria. Nor was there any significant correlation between the proteinuria and PaO₂, perhaps because the range of oxygen tensions was small.

Two hypotheses have been advanced for the cause of high altitude proteinuria. Firstly, the active tubular reabsorption of protein might be inhibited by hypoxia. This suggestion would be supported by the appearance in the urine of low molecular weight proteins such as alpha₁-microglobulin which are normally reabsorbed completely in the proximal tubule. However, the present study revealed alpha₁-microglobulin in the urines of only a few subjects while nearly all showed increased albuminuria. Secondly, an increase in capillary permeability secondary to hypoxia might lead to a greater filtered load of protein exceeding the reabsorptive capacity of the renal tubule.

In the present study we used intravenous L-lysine hydrochloride which is a strongly positively charged essential amino acid with a normal serum concentration of 0.15–0.26 mmol/l. The intravenous infusion of 30 g lysine would have increased the serum concentration to approximately 20 mmol/l. An important effect of intravenous lysine is the competitive inhibition of proximal protein reabsorption first described by Mogensen & Solling, whose protocol we followed. The inhibition is not complete so the estimate of albumin concentration in the glomerular filtrate following lysine infusion must be regarded as a minimum value.

Upright posture increases urinary albumin excretion from 2.6 to 5.9 µg/min. Similarly, albumin excretion will rise from 4 to 7 µg/min with oral water loading. However, though our subjects remained upright and were water-loaded, the changes we observed were much greater than would be accounted for by these factors.

The rates of urine flow after lysine were the same in subjects taking placebo or acetazolamide. However, the initial rates of urine flow were markedly different being much lower in the placebo group. It is unlikely that chronic acetazolamide treatment in normal subjects was having any basal diuretic effect. It is possible that acetazolamide causes a more rapid response to water loading.

The basal and post-lysine albumin excretion rates which we report are of the same order as those reported by Mogensen et al. in a group of diabetic patients with normal serum creatinine but elevated basal albumin excretion rates: 46.6 ± 18 µg/min rising to 366.8 ± 108 µg/min after lysine. The increased glomerular permeability to protein in diabetic patients can be related to morphological changes in the capillary basement membranes of the glomerulus. In contrast the rapid changes in permeability related to altitude make it unlikely that hypoxia is causing a similar lesion. It is unknown whether the alteration in glomerular permeability with hypoxia is mediated by a direct effect on the glomerular epithelial cells or secondarily by local hormonal effects on renal blood flow. If the factor which causes the increased permeability can be identified it raises the possibility of using an antagonist to treat or reduce the severity of acute mountain sickness.

Our results show that increased glomerular capillary permeability occurs in healthy men at high altitude and that it is the most important cause of proteinuria in the majority.

References

The origin of proteinuria at high altitude.

M. H. Winterborn, A. R. Bradwell, I. M. Chesner and G. T. Jones

doi: 10.1136/pgmj.63.737.179

Updated information and services can be found at:

http://pmj.bmj.com/content/63/737/179

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/